Chief Executive Officer
Previously, Randy Milby was Chief Executive Officer of CorMedix, Inc. (NYSE American:CRMD). Prior to CorMedix, Mr. Milby was co-founder and a managing director of WaterStone Bridge, LLC, a healthcare consulting services firm. In his 11-year tenure at DuPont Company, he held several management positions, most recently Global Business Director, Applied Biosciences. From 1998 through 1999, Mr. Milby was a Healthcare Analyst at Goldman Sachs & Company. Mr. Milby received his Pharmacy degree at the University of Kansas and his MBA from Washington University, St. Louis.
Trinh T. Le, M.B.A.
Head of Clinical Operations
Ms. Le is a clinical professional with over 25 years of broad operational and industry experience across the biotechnology, pharmaceuticals and contract research organization industries. She currently serves as a Principal at Collaborative Clinical Research Consulting, Inc. She has held senior level positions at Intellikine (acquired by Takeda), SGX Pharmaceuticals (acquired by Eli Lilly), Metabasis Therapeutics (acquired by Ligand) and Chiltern International. She earned an MBA from University of Redlands and a B.A. with a focus in biology and chemistry from University of California, San Diego.
Richard Lowenthal, M.Sc. M.B.A.
Head of Regulatory
Mr. Richard Lowenthal is an executive with over 28 years of Medicinal Product Development, Project Management, Regulatory Affairs and Quality Assurance experience in various roles at both small and large biotechnology or pharmaceutical companies. Mr. Lowenthal has extensive experience with strategic global development as well as product registration of biologics, new drugs and drug or biologic and device combinations in the United States, Europe and Japan. He also has extensive experience with global business collaborations and evaluation of product licensing or investment opportunities. Mr. Lowenthal, as a past FDA review in both the Division of Neuropharmacology Drug Products and Division of Oncology at the US FDA, has direct experience working within the Agency that facilitates interactions and an understanding of the FDA perspective.
Grace M. Furman, Ph.D. D.A.B.T.
Head of Toxicology
Grace received her Ph.D. in Biomedical Sciences with a specialization in toxicology from Northeastern University in Boston, MA (1992). She also holds a B.S. in toxicology (1986) and has been a Diplomate of the American Board of Toxicology since 2000. Grace is an active member of the American College of Toxicology (ACT) and has served ACT as a 2-term Council member (2009-2011 and 2017-2019), a member of the Nominating Committee (2008), as Secretary (2013-2014), and as co-chair (2017/2018) and chair (2018/2019) of the Education Committee. Grace is also an active member of the Society of Toxicology and the Southern California Chapter of the Society of Toxicology and has held several Executive Council positions, including President, within the Regional Chapter. Grace is chair emeritus of the San Diego Biotechnology Discussion Group and a founding member of San Diego's Women in Biosciences. Additionally, Grace designed and instructed the "Toxicology" classroom and distance-learning courses offered through University of California/San Diego Extension's Drug Discovery and Development and AMDET Process Certificate Programs (2005-2014).
Taunia Markvicka, Pharm.D., M.B.A.
Taunia has more than 25 years of pharmaceutical experience from regulatory/clinical to new product planning and commercialization. She served previously as Chief Commercial Officer (CCO) of Symbiomix Therapeutics, which was sold to Lupin Pharmaceuticals. She was also CCO at Pacira Pharmaceuticals, where she took the company public and successfully launched EXPAREL®. Prior to Pacira, Taunia held commercial leadership positions with Advantage Healthcare serving roles with Biovail and Reliant, The Medicines Company, and Allergan (formerly Watson Pharmaceuticals). She entered the pharmaceutical industry after completing a post-doctorate fellowship with Novartis. Taunia began her career as a hospital pharmacist.
Taunia earned her doctorate in pharmacy from the University of Nebraska Medical Center and post-doctoral fellowship with Rutgers University/Sandoz Pharmaceuticals. She went on to complete her MBA at St. Joseph’s University. She completed her Bachelors in Pharmacy at Creighton and practiced as a registered pharmacist prior to her pharmaceutical industry career.
Lynne A. Bui, M.D.
Lynne A. Bui, MD is the Co-Founder, President and CEO of Khloris Biosciences, Inc. She is a board-certiﬁed hematologist oncologist, seasoned entrepreneur, angel investor and drug developer, having unparalleled experience in basic, translational and clinical research spanning over 15 years with direct patient care and leading clinical development programs from preclinical IND enabling studies to Phase 1 to 3 registration studies for multiple approved drugs. She has held senior level positions at Exelixis, Onyx, and Intellikine, and has experience with small molecules, antibodies, dendritic cell vaccines, gene therapies, embryonic stem cells, and cell therapies. She is also the Founder and Chairman of Global Cancer Research Institute (GCRI) and GCRI Foundation. She received her M.D., internal medicine residency and hematology/oncology fellowship from UCLA School of Medicine, and her B.A. in molecular and cellular biology with an emphasis in neurobiology from UC Berkeley.
Sireesh Appajosyula, PharmD
Sireesh Appajosyula has over 20 years of experience in the pharmaceutical and biotechnology industry in multiple roles spanning R & D, medical affairs and commercial launches. He was the co-founder of HighPoint Therapeutics, Inc., a privately held pre-clinical stage biotechnology company, now a part of Hillstream Biopharma, looking at novel mechanism to inhibit stem-like cells in small cell lung cancer and other neuroendocrine tumors. Previously, he held various roles of increasing responsibilities at Salix Pharmaceuticals, Inc, acquired by Bausch Health Companies, Inc., as well as Amgen and Aventis Pharmaceuticals (acquired by Sanofi).
Mark Rosenberg, MD
Dr. Mark Rosenberg received his medical degree from Georgetown University and became board certified emergency room physician. He switched career paths after diagnosing his mother with stage IV non-small cell lung cancer. He began studying tumor metabolism, with a focus on the mechanisms of cancer resistance, as well as cancer stem cells and circulating tumor cells. Dr. Rosenberg is also the program director of an Integrative Cancer Fellowship, and is highly active in teaching advanced techniques for circumventing resistance. Dr. Rosenberg is featured in a PBS documentary entitled, “Those on the Front Lines of Cancer.”